Last reviewed · How we verify
VGN-R08b 1.68×10^14 vg
At a glance
| Generic name | VGN-R08b 1.68×10^14 vg |
|---|---|
| Sponsor | Shanghai Vitalgen BioPharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VGN-R08b 1.68×10^14 vg CI brief — competitive landscape report
- VGN-R08b 1.68×10^14 vg updates RSS · CI watch RSS
- Shanghai Vitalgen BioPharma Co., Ltd. portfolio CI